TELA Bio, Inc. (NASDAQ:TELA) Q4 2023 Earnings Call Transcript

Antony Koblish:

Vyvanse: We’re working on some of the really tight regional ones like Kaiser and things like that. I don’t have a good feel for when these are going to come. So far we’ve had excellent track record. We haven’t really been rejected anywhere. So I think it’s a matter of time that’s going to be driven off of when the bid process starts, how long it takes them to process and award the contracts, and then start the contracts. It’s generally a long process. So, like I said, this is the year of implementation more than new contracts. But we can keep the new contract machine going, and I expect it to be end of this year or sometime early next year, where you’ll start to see some additions.

Operator: Thank you. And I’m showing no further questions at this time and I’d like to turn the conference back over to Tony Koblish for any further remarks.

Antony Koblish: Yes. Thank you, Michelle and thank you to everybody for joining us and for your continued interest in TELA Bio. We look forward to catching up with you next time and have a great rest of your afternoon.

Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect.